CAPR250117C20000
- 0.20
- +0.07+53.85%
Capricor Therapeutics Newsroom
Maxim Group Maintains Capricor Therapeutics(CAPR.US) With Buy Rating, Maintains Target Price $25
Capricor Therapeutics: Promising Advances in Duchenne Cardiomyopathy Treatment Drive Buy Rating
Beyond The Numbers: 7 Analysts Discuss Capricor Therapeutics Stock
H.C. Wainwright Maintains Capricor Therapeutics(CAPR.US) With Buy Rating, Maintains Target Price $77
Express News | HC Wainwright & Co. Reiterates Buy on Capricor Therapeutics, Maintains $77 Price Target
Capricor Therapeutics Completes Submission Of Biologics License Application To FDA for Deramiocel
Express News | Capricor Therapeutics - Bla Submission Triggers $10 Mln Milestone Payment to Capricor From Nippon Shinyaku
Express News | Capricor Therapeutics Completes Submission of Biologics License Application to the U.S. FDA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy
RFK Jr. Could Prove a Surprise Boon for Stem-cell Stocks With Pivotal Year Ahead
Stem Cells Poised for Success in 2025 as Regulatory Environment Looks More Favorable -- Market Talk
JonesTrading Maintains Capricor Therapeutics(CAPR.US) With Buy Rating, Maintains Target Price $40
12 Health Care Stocks Moving In Thursday's Pre-Market Session
America's Car-Mart Posts Upbeat Sales, Joins Methode Electronics, Verint Systems, Brown-Forman And Other Big Stocks Moving Higher On Thursday
Capricor Therapeutics, Inc. (NASDAQ:CAPR): Are Analysts Optimistic?
Capricor Therapeutics to Present at Upcoming Investor Conferences
Capricor Wins Key EU Designations for the Lead Asset
Capricor Therapeutics Granted Orphan Drug And ATMP Status For Deramiocel By EMA
Express News | Capricor Therapeutics Inc - Expects to Complete Bla Submission by End of 2024
Express News | Capricor Therapeutics Granted Orphan Drug and Atmp Status for Deramiocel by European Medicines Agency
Capricor Therapeutics Analyst Ratings